Scientific equipment maker Thermo Fisher Scientific will buy rival Life Technologies Corp. for approximately $13.6 billion in a deal that combines two of the biggest companies in the field of genomics and cell biology.

Thermo Fisher will pay Life Technologies shareholders $76 for each share of stock. Thermo Fisher will also assume about $2.2 billion in debt, bringing the total deal value to about $15.8 billion.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]